Companies in the News

6.20.2017

South San Francisco, Calif. – June 20, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, today announced it has received a grant from the National Institute of Neurological Disorders and Stroke (NINDS) o...

6.20.2017

SAN DIEGO, June 20, 2017 /PRNewswire/ -- eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cance...

6.7.2017

BLACKTHORN’S BTRX-246040 NOCICEPTIN PROGRAM IS FIRST MOLECULE AND CLINICAL PROGRAM TO INCORPORATE MINDSTRONG HEALTH’S PATENTED TECHNOLOGY PLATFORM

South San Francisco, Calif. – June 7, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments...

Please reload